Compare QCLS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCLS | NSRX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | Israel |
| Employees | 2 | 7 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 32.2M |
| IPO Year | N/A | N/A |
| Metric | QCLS | NSRX |
|---|---|---|
| Price | $4.18 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 548.3K | 79.9K |
| Earning Date | 04-15-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $1.98 |
| 52 Week High | $8.17 | $9.99 |
| Indicator | QCLS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 50.24 |
| Support Level | $4.00 | $2.04 |
| Resistance Level | $4.89 | $3.48 |
| Average True Range (ATR) | 0.45 | 0.25 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 34.07 | 36.63 |
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.